|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-05
|
$336,565
|
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-03
|
$349,694
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
1R01CA211328-01
|
$404,888
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Developing a translational pipeline for NF1-mutant malignancies
|
5U01CA202943-03
|
$235,046
|
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Determining the Epigenetic Mechanisms Driving Tissue Factor (F3) Upregulation and its Role in Metastatic Osteosarcoma
|
5F31CA213965-02
|
$44,524
|
|
BAYLES, IAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining novel drivers and predictive signatures of metastasis in osteosarcoma th
|
5F30CA186633-05
|
$49,524
|
|
MORROW, JAMES
|
CASE WESTERN RESERVE UNIVERSITY
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
5K08CA179084-05
|
$112,331
|
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion
|
5R01CA189299-04
|
$338,550
|
|
KELLER, CHARLES
|
CHILDREN'S CANCER THERAPY DEVELOP/INST
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$83,611
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,352,827
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
5R01CA207983-02
|
$449,691
|
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-23
|
$214,456
|
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
|
5U01CA217858-02
|
$1,314,469
|
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer
|
5F31CA192891-05
|
$49,524
|
|
PRICE, JESSICA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
|
5K08CA191058-04
|
$177,120
|
|
JESELSOHN, RINATH
|
DANA-FARBER CANCER INST
|
|
Targeting intratumor heterogeneity in breast cancer
|
5R35CA197623-04
|
$1,157,073
|
|
POLYAK, KORNELIA
|
DANA-FARBER CANCER INST
|
|
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
|
5P01CA206978-03
|
$1,755,838
|
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
|
5R35CA210057-03
|
$1,007,233
|
|
ZHAO, JEAN
|
DANA-FARBER CANCER INST
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Perfluorocarbon Nanodroplets for the Detection and Treatment of Nodal Metastases
|
5F30CA216939-02
|
$49,524
|
|
YARMOSKA, STEVEN
|
EMORY UNIVERSITY
|
|
Microdevice-Armed Macrophage For Treating Cancer
|
5R03CA202334-02
|
$70,610
|
|
GUAN, JINGJIAO
|
FLORIDA STATE UNIVERSITY
|
|
Overcoming stromal barriers to therapeutics in pancreas cancer
|
5R01CA161112-08
|
$513,402
|
|
HINGORANI, SUNIL
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Late Effects of Treatment in Wilms Tumor Survivors and Offspring
|
3R01CA054498-25S1
|
$44,259
|
$44,259
|
LEISENRING, WENDY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-05
|
$303,118
|
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
Investigating the Functional Consequences of SMARCE1 loss in Clear Cell Meningioma
|
1F31CA228441-01
|
$38,080
|
|
ST PIERRE, ROODOLPH
|
HARVARD UNIVERSITY
|
|
The role of Lin28/let 7 pathway in Wilms' tumor
|
5F99CA212487-02
|
$31,994
|
$31,994
|
YERMALOVICH, ALENA
|
HARVARD UNIVERSITY
|
|
Cholesterol promotes breast cancer progression: establishing the mechanisms
|
5K08CA190770-05
|
$168,571
|
|
GALLAGHER, EMILY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Functional interactions between AKT and HSF-1 in breast cancer progression
|
5K22CA207575-02
|
$162,000
|
|
CARPENTER, RICHARD
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
|
2R01CA167291-06
|
$493,726
|
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Nanosystems Biology Cancer Center
|
5U54CA199090-05
|
$2,073,361
|
|
HEATH, JAMES
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
|
Cancer Center Support (CORE) Grant
|
5P30CA034196-33
|
$2,100,000
|
|
LIU, EDISON
|
JACKSON LABORATORY
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
5R01CA219880-02
|
$670,182
|
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma
|
5R01CA189163-05
|
$1,372,351
|
|
FARIES, MARK
|
JOHN WAYNE CANCER INSTITUTE
|
|
SPORE in Prostate Cancer
|
5P50CA058236-23
|
$1,881,489
|
|
DENMEADE, SAMUEL
|
JOHNS HOPKINS UNIVERSITY
|
|
The Johns Hopkins Physical Sciences Oncology Center
|
5U54CA210173-03
|
$1,921,408
|
|
WIRTZ, DENIS
|
JOHNS HOPKINS UNIVERSITY
|
|
Rapid Protease Profiling with a Multiplex Electronic Method for Detection of Metastatic Triple-Negative Breast Cancer
|
5R01CA217657-02
|
$380,137
|
|
LI, JUN
|
KANSAS STATE UNIVERSITY
|
|
Integrated models for metastatic phenotype and outcome prediction in osteosarcoma
|
5R01CA178908-05
|
$356,999
|
|
SPENTZOS, DIMITRIOS
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
The Role of PlexinA1 in Rhabdomyosarcoma
|
1F32CA228366-01
|
$59,038
|
|
WELKER, ALESSANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors
|
5U54CA210180-03
|
$2,046,454
|
|
WHITE, FOREST
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$21,000
|
N/A
|
National Institutes of Health
|
|
Oncogenic Met Signaling in Urologic Malignancies
|
ZIA BC 011124
|
$356,352
|
$7,127
|
Bottaro, Donald
|
CCR (NCI)
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$9,496
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Identification of Novel Mutations In Pediatric Cancers
|
ZIA BC 010998
|
$511,155
|
$25,558
|
Khan, Javed
|
CCR (NCI)
|
|
Growth-Differentiation Factors in Organogenesis
|
ZIA BC 005093
|
$748,932
|
$337,020
|
Perantoni, Alan
|
CCR (NCI)
|
|
Identification of Genetic Factors Associated with Infectious Diseases
|
ZIA BC 010297
|
$313,024
|
$31,302
|
Winkler, Cheryl
|
CCR (NCI)
|
|
Retrospective NCI Phantom-Monte Carlo Dosimetry for Late Effects in Wilms Tumor
|
1R01CA219013-01
|
$632,028
|
$632,028
|
KALAPURAKAL, JOHN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-23S1
|
$204,369
|
$6,131
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
Total relevant funding to Wilm's Tumor for this search: $4,995,401
|